News Briefing channel feed – Endpoints News

News Briefing channel feed

Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

Last year

Valneva tops up loan by $100M; Ipsen gets a voucher

Last year

Precision BioSciences hands global rights to CAR-T candidate; Sagimet closes underwriter’s option to buy stock

Last year

Sinovac's Covid vaccine sales nosedive; Gracell trims pipeline, starts lupus study

Last year

Akebia notifies SEC it will be late filing Q2 earnings; Surrozen cuts two early programs

Last year

HIV cell therapy biotech Addimmune to go public via SPAC merger; WHO names new Covid-19 'variant of interest'

Last year

Eli Lilly’s Mounjaro peak sales could now top $68B – analyst; Elon Musk’s brain-chip company reels in $280M

Last year

Beam takes its time to the clinic; Aspen gets clearance to test Parkinson's cell therapy in humans

Last year

BioNTech expands ADC deal with DualityBio; Gracell and IO Biotech get private placements from a slew of investors

Last year

George Church-endorsed startup seeks 'alternatives'; DOJ closes Onpattro marketing investigation

Last year

Inovio prunes headcount again; Aulos adds to Series A

Last year

Annexon lays out more GA drug data; Okyo Pharma pulls back public offering

Last year

Ionis widens eplontersen agreement with AstraZeneca; Inozyme looks to get $60M in public offering

Last year

Bristol Myers invests $35M into Immatics; FibroGen names new CEO

Last year

Quince buys a rare disease biotech; Heron reduces headcount

Last year

BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave Therapeutics’ assets

Last year

Ginkgo Bioworks handed a DARPA manufacturing contract; Merck hits a primary endpoint for Keytruda in first-line cervical cancer

Last year

Aridis to delist from Nasdaq; Bicycle closes $200M+ offering

Last year

Travere inks bile acid divestiture; Madrigal completes NASH approval request

Last year

Iovance closes $172.5M offering; Veklury approved for Covid-19 patients with severe renal disease

Last year

Bicycle rides to $200M payday, while lung disease biotech raises $80M

Last year

Bristol Myers touts PhIII Opdivo win in urothelial carcinoma; Liminal BioSciences goes private

Last year

Bristol Myers reinforces neuroscience deals; Iovance prices $150M public offering

Last year

The $2.7B Precision/Eli Lilly deal gets modified; Abeona closes $25M direct offering

Last year

First page Previous page 15 16 171819 20 21 Next page Last page